

RECEIVED

SEP 26 1998

MATRIX CUSTOMER
SERVICE CENTER

IN THE UNITED STATES PATENT OFFICE

Express Mail EL008174427US

In re Application of Klimko et al.


Serial No. 08/917,795

Filed: August 21, 1997

Examiner: R. Raymond

Group Art Unit: 1611

For: Use of Cloprostetol and Fluprostenol Analogues
To Treat Glaucoma and Ocular Hypertension



TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

A Response and Terminal Disclaimer are attached. In connection with the Terminal Disclaimer, the Commissioner is requested to charge the \$110.00 fee required under 37 CFR 1.20(d) and any other fees which may be required to Deposit Account No. 01-0682. A duplicate of this letter is attached.

Respectfully submitted,

ALCON LABORATORIES, INC.

Date: 9-15-98

By Barry L. Copeland
Barry L. Copeland
Registration No. 34,801

ADDRESS FOR CORRESPONDENCE:

Barry L. Copeland [Mail Code Q-148]
Intellectual Property Law & R&D Counsel
ALCON LABORATORIES, INC.
6201 South Freeway
Fort Worth, Texas 76134-2099
Phone: (817) 551-4322
Attorney Docket No.:1407B